Session Details
[27-59-pm1]Informatics, Computational chemistry 3/Radioactive compounds 1
Fri. Mar 27, 2026 1:10 PM - 3:10 PM JST
Fri. Mar 27, 2026 4:10 AM - 6:10 AM UTC
Fri. Mar 27, 2026 4:10 AM - 6:10 AM UTC
Room 59 (4001, Bldg. 4, Area 4 [B1F]) (2)
Discusser: Kento Kannaka, Shuichi Fukuyoshi
[27-59-pm1-11S]Complex structure and interaction analysis of SARS-CoV 3CLpro and flavonoid compounds using molecular simulation
○Kotone Kuruma1, Kazumi Akasaka1, Tohru Daikoku1, Hiroaki Saito1 (1. Faculty of Pharmaceutical, Hokuriku University)
[27-59-pm1-12S]Computational elucidation of the effects of the genetic polymorphisms on the structures of dihydropyrimidinase based on molecular dynamics simulation
○Yusuke Sakakibara1, Ayato Mizuno1, Tomoki Nakayoshi1,2, Eiji Hishinuma3, Masahiro Hiratsuka3,4, Koichi Kato1,5, Akifumi Oda1 (1. Fac. Pharm., Meijo Univ, 2. Inst. Adv. Res., Nagoya Univ, 3. INGEM, Tohoku Univ, 4. Grad. Sch. Pharm. Sci., Tohoku Univ, 5. Fac. Pharm. Sci., Shonan Univ. Med. Sci)
[27-59-pm1-13]Interaction analysis for adsorptions of drug molecules on surfaces of cellulose Iβ crystal by molecular dynamics simulation
○Daichi Hayakawa1, Chihiro Sato2, Hiroaki Gouda1 (1. Showa Med. Univ. Grad. Sch. Pharm., 2. Showa Med. Univ. Sch. Pharm.)
[27-59-pm1-14]Computational analyses of the effects of genetic polymorphisms in N-acetyltransferase 2 on isoniazid recognition using molecular dynamics simulations
○Tomoki Nakayoshi1,2,3, Ayato Mizuno1, Koichi Kato1,4, Akifumi Oda1 (1. Fac. Pharm., Meijo Univ., 2. Inst. Adv. Res., Nagoya Univ., 3. Grad. Sch. Inf. Sci., Hiroshima City Univ., 4. Fac. Pharm. Sci., Shonan Univ. Med. Sci.)
[27-59-pm1-15]Molecular Dynamics Analysis of the μ-Opioid Receptor–Morphine Complex
○HIROYOSHI ESAKI1, ITSUKI KANATA1, KENTA TOBARU1, YASUHARU NAKANE1, AYAKI YOSHIDA1, KAZUAKI FUKUSHIMA1 (1. Hyogo Med. Univ.)
[27-59-pm1-16S]Development of a novel 211At-labeled agent targeting neurotensin receptor 1 for targeted α-particle therapy
○Masayoshi Otsu1, Kosuke Saito1, Kazuma Nakashima1, Hiroyuki Fujimoto2, Masashi Murakami3, Kazuhiro Ooe3, Atsushi Toyoshima3, Hiroyuki Watanabe1, Masahiro Ono1 (1. Grad. Sch. Pharm. Sci., Kyoto Univ., 2. Agency for Health, Safety and Environment, Kyoto Univ., 3. Institute for Radiation Sciences, Univ. Osaka)
[27-59-pm1-17]Evaluation of the efficacy of 5F-αMe-3BPA as a candidate agent for Boron Neutron Capture Therapy
○Takashi Temma1,2, Saki Iritani2, Naoya Kondo2,3, Fuko Hirano2, Kensuke Suzuki4, Anna Miyazaki2 (1. Inst. Integ. Radiat. Nucl. Sci., Kyoto Univ., 2. Facul. Pharm. Sci., Osaka Med. Pharm. Univ., 3. NIR-PIT Res. Inst., Kansai Med. Univ., 4. Stella Pharma)
[27-59-pm1-18S]Development of novel radioligand with bivalent albumin binder for diagnosis and therapy of neuroendocrine tumors
○Takuma Yamane1, Kazuma Nakashima1, Nobuki Kazuta1, Hiroyuki Watanabe1, Masahiro Ono1 (1. Grad. Sch. Pharm. Sci., Kyoto Univ.)
[27-59-pm1-19S]Evaluation of the effect of Auger electrons on amyloid-β aggregation process
○Rikuto Kashiyama1, Hiroyuki Watanabe1, Takahiro Akasaka1, Kazuma Nakashima1, Masahiro Ono1 (1. Grad. Sch. Pharm. Sci., Kyoto Univ.)
[27-59-pm1-20S]Synthesis of radioiodine-labelled probe targeting MUC16 for diagnostic nuclear medicine of TNBC
○Hiroto Ichikawa1, Hidekazu Kawashima1, Sakino Tanida1, Fumiko Hara2, Shinya Takada2, Yuto Kondou3, Yusuke Yagi4, Hiroyuki Kimura5, Masayori Hagimori2 (1. Kyoto Pharmaceutical University, 2. School of Pharmaceutical Sciences, Mukogawa Women's University, 3. Advanced Clinical Research Center, Fukushima Medical University, 4. Faculty Medical Science, Kyoto University Medical Science, 5. Agency for Health, Safety and Environment, Kyoto University)